CYCLERION THERAPEUTICS, INC. Investment Income, Nonoperating
CYCLERION THERAPEUTICS, INC. (CYCN) reported Investment Income, Nonoperating of $588.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2021-02-25
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2020-12-31 was -$4.00K, a 100.75% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2020-09-30 was $93.00K, a 86.70% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2020-06-30 was $138.00K, a 82.75% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for the quarter ending 2020-03-31 was $361.00K.
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for fiscal 2020 was $588.00K, a 71.02% decline from fiscal 2019.
- CYCLERION THERAPEUTICS, INC. investment income, nonoperating for fiscal 2019 was $2.03M.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $89.00K derived: sum of 2 quarters · filed 2021-02-25 | $227.00K derived: sum of 3 quarters · filed 2021-02-25 | $588.00K 10-K · filed 2021-02-25 |
| 2020-09-30 | $93.00K 10-Q · filed 2020-11-05 | $231.00K derived: sum of 2 quarters · filed 2020-11-05 | $592.00K 10-Q · filed 2020-11-05 | $1.12M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | $138.00K 10-Q · filed 2020-08-03 | $499.00K 10-Q · filed 2020-08-03 | $1.03M derived: sum of 3 quarters · filed 2021-02-25 | $1.73M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | $361.00K 10-Q · filed 2020-05-04 | $892.00K derived: sum of 2 quarters · filed 2021-02-25 | $1.59M derived: sum of 3 quarters · filed 2021-02-25 | $2.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.23M derived: sum of 2 quarters · filed 2021-02-25 | $2.03M derived: sum of 3 quarters · filed 2021-02-25 | $2.03M 10-K · filed 2021-02-25 |
| 2019-09-30 | $699.00K 10-Q · filed 2020-11-05 | $1.50M derived: sum of 2 quarters · filed 2020-11-05 | $1.50M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $800.00K 10-Q · filed 2020-08-03 | $800.00K 10-Q · filed 2020-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |